drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00692 | DB11827 | 274 | 433 | [
"DDInter1448",
"DDInter669"
] | Phentolamine | Ertugliflozin | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
274,
24,
433
]
],
[
[
274,
63,
1020
],
[
1020,
24,
433
]
],
[
[
274,
24,
1508
],
[
1508,
24,
433
]
],
[
[
274,
23,
1254
],
[
1254,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine and ... |
DB00790 | DB01142 | 664 | 1,264 | [
"DDInter1431",
"DDInter593"
] | Perindopril | Doxepin | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
664,
24,
1264
]
],
[
[
664,
24,
401
],
[
401,
24,
1264
]
],
[
[
664,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
664,
21,
29226
],
[
29226,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Perindopril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Perindopril (Compoun... |
DB06650 | DB06674 | 1,500 | 908 | [
"DDInter1324",
"DDInter837"
] | Ofatumumab | Golimumab | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1500,
25,
908
]
],
[
[
1500,
24,
200
],
[
200,
63,
908
]
],
[
[
1500,
63,
1136
],
[
1136,
24,
908
]
],
[
[
1500,
25,
334
],
[
334,
... | [
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candi... | Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab ... |
DB00006 | DB06209 | 942 | 256 | [
"DDInter217",
"DDInter1508"
] | Bivalirudin | Prasugrel | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
942,
25,
256
]
],
[
[
942,
23,
944
],
[
944,
62,
256
]
],
[
[
942,
24,
901
],
[
901,
24,
256
]
],
[
[
942,
24,
1427
],
[
1427,
6... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipra... |
DB00550 | DB08826 | 99 | 1,292 | [
"DDInter1541",
"DDInter489"
] | Propylthiouracil | Deferiprone | A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
99,
25,
1292
]
],
[
[
99,
21,
28762
],
[
28762,
60,
1292
]
],
[
[
99,
63,
482
],
[
482,
25,
1292
]
],
[
[
99,
24,
372
],
[
372,
... | [
[
[
"Propylthiouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Propylthiouracil",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused b... | Propylthiouracil (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Deferiprone (Compound)
Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone... |
DB00108 | DB11627 | 1,066 | 1,367 | [
"DDInter1268",
"DDInter860"
] | Natalizumab | Hepatitis B Vaccine (Recombinant) | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1066,
24,
1367
]
],
[
[
1066,
25,
1083
],
[
1083,
24,
1367
]
],
[
[
1066,
64,
1648
],
[
1648,
24,
1367
]
],
[
[
1066,
25,
119
],
[
119... | [
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
... | Natalizumab may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Natalizumab may lead to a major life threatening interaction when taken with Aldesleukin and Aldesl... |
DB00607 | DB11718 | 1,249 | 927 | [
"DDInter1256",
"DDInter640"
] | Nafcillin | Encorafenib | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1249,
25,
927
]
],
[
[
1249,
24,
1491
],
[
1491,
24,
927
]
],
[
[
1249,
63,
1010
],
[
1010,
24,
927
]
],
[
[
1249,
25,
484
],
[
484,
... | [
[
[
"Nafcillin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostauri... | Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Meflo... |
DB00363 | DB08899 | 695 | 129 | [
"DDInter419",
"DDInter649"
] | Clozapine | Enzalutamide | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
695,
25,
129
]
],
[
[
695,
25,
918
],
[
918,
1,
129
]
],
[
[
695,
6,
8374
],
[
8374,
45,
129
]
],
[
[
695,
23,
112
],
[
112,
23,... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{... | Clozapine may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Clozapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Clozapine may cause a minor interaction that can limit clinical effects whe... |
DB00759 | DB00808 | 1,620 | 1,605 | [
"DDInter1783",
"DDInter916"
] | Tetracycline | Indapamide | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Minor | 0 | [
[
[
1620,
23,
1605
]
],
[
[
1620,
62,
811
],
[
811,
1,
1605
]
],
[
[
1620,
6,
8374
],
[
8374,
45,
1605
]
],
[
[
1620,
1,
1669
],
[
1669,
... | [
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
],
[
... | Tetracycline may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Tetracycline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indapamide (Compound)
Tetracycline (Compound) resembles Minocycline (Compound) and Min... |
DB00530 | DB12147 | 1,195 | 241 | [
"DDInter667",
"DDInter661"
] | Erlotinib | Erdafitinib | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Moderate | 1 | [
[
[
1195,
24,
241
]
],
[
[
1195,
24,
384
],
[
384,
24,
241
]
],
[
[
1195,
24,
982
],
[
982,
63,
241
]
],
[
[
1195,
24,
286
],
[
286,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivoside... |
DB00222 | DB08886 | 245 | 637 | [
"DDInter825",
"DDInter126"
] | Glimepiride | Asparaginase Erwinia chrysanthemi | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
245,
24,
637
]
],
[
[
245,
24,
640
],
[
640,
24,
637
]
],
[
[
245,
24,
1385
],
[
1385,
63,
637
]
],
[
[
245,
23,
1347
],
[
1347,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ac... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00842 | DB01041 | 686 | 770 | [
"DDInter1359",
"DDInter1789"
] | Oxazepam | Thalidomide | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feat... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
686,
24,
770
]
],
[
[
686,
6,
7524
],
[
7524,
45,
770
]
],
[
[
686,
21,
28789
],
[
28789,
60,
770
]
],
[
[
686,
24,
849
],
[
849,
... | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Oxazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Oxazepam (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Oxazepam (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00631 | DB01132 | 372 | 1,130 | [
"DDInter405",
"DDInter1472"
] | Clofarabine | Pioglitazone | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
372,
24,
1130
]
],
[
[
372,
7,
2475
],
[
2475,
57,
1130
]
],
[
[
372,
21,
28996
],
[
28996,
60,
1130
]
],
[
[
372,
24,
242
],
[
242,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Clofarabine",
"{u} (Compound) upregulates {v} (Gene)",
"RGS2"
],
[
"RGS2",
"{u} (Gene) is downregulated by {v... | Clofarabine (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is downregulated by Pioglitazone (Compound)
Clofarabine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Pioglitazone (Compound)
Clofarabine may cause a moderate interaction that could exac... |
DB00783 | DB01082 | 1,438 | 1,448 | [
"DDInter679",
"DDInter1713"
] | Estradiol | Streptomycin | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
1438,
24,
1448
]
],
[
[
1438,
21,
28882
],
[
28882,
60,
1448
]
],
[
[
1438,
24,
361
],
[
361,
24,
1448
]
],
[
[
1438,
63,
91
],
[
91,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Estradiol",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased"... | Estradiol (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Streptomycin (Compound)
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate di... |
DB00530 | DB08880 | 1,195 | 1,510 | [
"DDInter667",
"DDInter1771"
] | Erlotinib | Teriflunomide | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1195,
25,
1510
]
],
[
[
1195,
24,
129
],
[
129,
63,
1510
]
],
[
[
1195,
24,
697
],
[
697,
24,
1510
]
],
[
[
1195,
63,
752
],
[
752,
... | [
[
[
"Erlotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalut... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital an... |
DB01611 | DB11989 | 1,487 | 1,434 | [
"DDInter893",
"DDInter183"
] | Hydroxychloroquine | Benznidazole | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
1487,
24,
1434
]
],
[
[
1487,
24,
788
],
[
788,
24,
1434
]
],
[
[
1487,
24,
148
],
[
148,
63,
1434
]
],
[
[
1487,
63,
1477
],
[
1477,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavasta... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB06448 | DB09143 | 171 | 313 | [
"DDInter1087",
"DDInter1701"
] | Lonafarnib | Sonidegib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
171,
25,
313
]
],
[
[
171,
63,
837
],
[
837,
23,
313
]
],
[
[
171,
64,
478
],
[
478,
24,
313
]
],
[
[
171,
25,
1478
],
[
1478,
2... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantopraz... | Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Lonafarnib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a... |
DB01224 | DB01619 | 623 | 830 | [
"DDInter1553",
"DDInter1441"
] | Quetiapine | Phenindamine | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
623,
24,
830
]
],
[
[
623,
40,
11321
],
[
11321,
40,
830
]
],
[
[
623,
63,
537
],
[
537,
40,
830
]
],
[
[
623,
63,
13
],
[
13,
2... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Metixene"
],
[
"Metixene",
"{u} (Compound) resembles ... | Quetiapine (Compound) resembles Metixene (Compound) and Metixene (Compound) resembles Phenindamine (Compound)
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Quetiapine may cause a moderate interaction that c... |
DB00635 | DB11248 | 1,573 | 1,193 | [
"DDInter1515",
"DDInter1965"
] | Prednisone | Zinc gluconate | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
1573,
23,
1193
]
],
[
[
1573,
24,
1531
],
[
1531,
23,
1193
]
],
[
[
1573,
40,
167
],
[
167,
23,
1193
]
],
[
[
1573,
24,
270
],
[
270,
... | [
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Prednisone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction t... |
DB00227 | DB11986 | 1,463 | 484 | [
"DDInter1098",
"DDInter648"
] | Lovastatin | Entrectinib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1463,
24,
484
]
],
[
[
1463,
24,
112
],
[
112,
23,
484
]
],
[
[
1463,
24,
466
],
[
466,
62,
484
]
],
[
[
1463,
24,
63
],
[
63,
2... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and... |
DB01066 | DB09104 | 1,462 | 286 | [
"DDInter316",
"DDInter1118"
] | Cefditoren | Magnesium hydroxide | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1462,
24,
286
]
],
[
[
1462,
63,
752
],
[
752,
23,
286
]
],
[
[
1462,
24,
1283
],
[
1283,
24,
286
]
],
[
[
1462,
63,
1096
],
[
1096,
... | [
[
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],... | Cefditoren may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Cefditoren may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxid... |
DB09135 | DB09293 | 1,211 | 116 | [
"DDInter967",
"DDInter954"
] | Ioxilan | Iodide I-131 | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1211,
24,
116
]
],
[
[
1211,
24,
278
],
[
278,
63,
116
]
],
[
[
1211,
64,
485
],
[
485,
24,
116
]
],
[
[
1211,
25,
1399
],
[
1399,
... | [
[
[
"Ioxilan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Ioxilan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
[
... | Ioxilan may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Ioxilan may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may caus... |
DB00518 | DB09098 | 510 | 98 | [
"DDInter35",
"DDInter1700"
] | Albendazole | Somatrem | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
510,
24,
98
]
],
[
[
510,
62,
608
],
[
608,
23,
98
]
],
[
[
510,
24,
159
],
[
159,
63,
98
]
],
[
[
510,
24,
34
],
[
34,
24,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
... | Albendazole may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrect... |
DB11718 | DB11837 | 927 | 1,297 | [
"DDInter640",
"DDInter1351"
] | Encorafenib | Osilodrostat | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
927,
24,
1297
]
],
[
[
927,
63,
1135
],
[
1135,
23,
1297
]
],
[
[
927,
62,
112
],
[
112,
23,
1297
]
],
[
[
927,
24,
1320
],
[
1320,
... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[... | Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Encorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metro... |
DB00794 | DB04868 | 759 | 478 | [
"DDInter1521",
"DDInter1293"
] | Primidone | Nilotinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
759,
25,
478
]
],
[
[
759,
24,
1468
],
[
1468,
63,
478
]
],
[
[
759,
6,
6017
],
[
6017,
45,
478
]
],
[
[
759,
21,
28762
],
[
28762,
... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Primidone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Primidone (Compound) cau... |
DB05015 | DB10315 | 1,077 | 1,137 | [
"DDInter174",
"DDInter1127"
] | Belinostat | Measles virus vaccine live attenuated | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
1077,
25,
1137
]
],
[
[
1077,
64,
581
],
[
581,
25,
1137
]
],
[
[
1077,
24,
384
],
[
384,
25,
1137
]
],
[
[
1077,
63,
1184
],
[
1184,
... | [
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
... | Belinostat may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisi... |
DB01085 | DB08868 | 562 | 1,011 | [
"DDInter1465",
"DDInter737"
] | Pilocarpine | Fingolimod | A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist.[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine is used to treat dry mouth and various ophthalmic conditions, i... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Moderate | 1 | [
[
[
562,
24,
1011
]
],
[
[
562,
6,
6365
],
[
6365,
45,
1011
]
],
[
[
562,
21,
29097
],
[
29097,
60,
1011
]
],
[
[
562,
24,
1276
],
[
1276,... | [
[
[
"Pilocarpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Pilocarpine",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)... | Pilocarpine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Fingolimod (Compound)
Pilocarpine (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Fingolimod (Compound)
Pilocarpine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alec... |
DB00468 | DB00694 | 1,424 | 51 | [
"DDInter1557",
"DDInter485"
] | Quinine | Daunorubicin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
1424,
24,
51
]
],
[
[
1424,
6,
7950
],
[
7950,
45,
51
]
],
[
[
1424,
7,
12111
],
[
12111,
46,
51
]
],
[
[
1424,
7,
5998
],
[
5998,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound)
Quinine (Compound) upregulates MSRA (Gene) and MSRA (Gene) is upregulated by Daunorubicin (Compound)
Quinine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Daunorubicin (Compound)
Quinine (Compound) ca... |
DB00352 | DB00660 | 482 | 1,470 | [
"DDInter1814",
"DDInter1163"
] | Tioguanine | Metaxalone | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous... | Moderate | 1 | [
[
[
482,
24,
1470
]
],
[
[
482,
21,
28826
],
[
28826,
60,
1470
]
],
[
[
482,
24,
663
],
[
663,
24,
1470
]
],
[
[
482,
24,
1532
],
[
1532,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metaxalone"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused... | Tioguanine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Metaxalone (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Metax... |
DB01105 | DB01563 | 222 | 680 | [
"DDInter1665",
"DDInter349"
] | Sibutramine | Chloral hydrate | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
222,
24,
680
]
],
[
[
222,
24,
272
],
[
272,
24,
680
]
],
[
[
222,
63,
1614
],
[
1614,
24,
680
]
],
[
[
222,
25,
593
],
[
593,
2... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Na... |
DB01367 | DB06764 | 1,163 | 1,090 | [
"DDInter1572",
"DDInter1787"
] | Rasagiline | Tetryzoline (nasal) | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1163,
24,
1090
]
],
[
[
1163,
24,
144
],
[
144,
63,
1090
]
],
[
[
1163,
63,
688
],
[
688,
24,
1090
]
],
[
[
1163,
64,
222
],
[
222,
... | [
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
... | Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Rasagili... |
DB00405 | DB06016 | 128 | 1,508 | [
"DDInter517",
"DDInter300"
] | Dexbrompheniramine | Cariprazine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
128,
24,
1508
]
],
[
[
128,
63,
1242
],
[
1242,
24,
1508
]
],
[
[
128,
24,
1507
],
[
1507,
24,
1508
]
],
[
[
128,
74,
1594
],
[
1594,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dicy... |
DB00834 | DB08901 | 932 | 1,468 | [
"DDInter1215",
"DDInter1492"
] | Mifepristone | Ponatinib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
932,
24,
1468
]
],
[
[
932,
25,
478
],
[
478,
24,
1468
]
],
[
[
932,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
932,
7,
5057
],
[
5057,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotini... | Mifepristone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Mifepristone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Mifepristone (Compound) upregulat... |
DB00655 | DB12010 | 559 | 214 | [
"DDInter682",
"DDInter785"
] | Estrone | Fostamatinib | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
559,
24,
214
]
],
[
[
559,
24,
723
],
[
723,
24,
214
]
],
[
[
559,
63,
1573
],
[
1573,
24,
214
]
],
[
[
559,
24,
1017
],
[
1017,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Estrone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone... |
DB00075 | DB15091 | 541 | 676 | [
"DDInter1250",
"DDInter1901"
] | Muromonab | Upadacitinib | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
541,
25,
676
]
],
[
[
541,
23,
1193
],
[
1193,
23,
676
]
],
[
[
541,
24,
1430
],
[
1430,
24,
676
]
],
[
[
541,
63,
1184
],
[
1184,
... | [
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Muromonab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glu... | Muromonab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and ... |
DB06595 | DB08827 | 1,491 | 990 | [
"DDInter1214",
"DDInter1085"
] | Midostaurin | Lomitapide | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
1491,
24,
990
]
],
[
[
1491,
64,
1080
],
[
1080,
1,
990
]
],
[
[
1491,
23,
1135
],
[
1135,
62,
990
]
],
[
[
1491,
24,
1409
],
[
1409,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivapt... | Midostaurin may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effect... |
DB00860 | DB09038 | 891 | 1,450 | [
"DDInter1513",
"DDInter636"
] | Prednisolone | Empagliflozin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
891,
24,
1450
]
],
[
[
891,
40,
1103
],
[
1103,
23,
1450
]
],
[
[
891,
63,
461
],
[
461,
24,
1450
]
],
[
[
891,
23,
659
],
[
659,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could ... |
DB00712 | DB01254 | 1,274 | 1,213 | [
"DDInter764",
"DDInter484"
] | Flurbiprofen (ophthalmic) | Dasatinib | Flurbiprofen can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1274,
37,
1213
]
],
[
[
1274,
7,
6855
],
[
6855,
46,
1213
]
],
[
[
1274,
18,
3439
],
[
3439,
46,
1213
]
],
[
[
1274,
21,
28882
],
[
28... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) upregulates {v} (Gene)",
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Flurbiprofen may lead to a major life threatening interaction when taken with Dasatinib
Flurbiprofen (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Dasatinib (Compound)
Flurbiprofen (Co... |
DB00366 | DB04948 | 1,594 | 1,084 | [
"DDInter600",
"DDInter1083"
] | Doxylamine | Lofexidine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
1594,
24,
1084
]
],
[
[
1594,
24,
1617
],
[
1617,
1,
1084
]
],
[
[
1594,
24,
1311
],
[
1311,
24,
1084
]
],
[
[
1594,
74,
701
],
[
701,... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interact... |
DB06589 | DB06616 | 1,250 | 594 | [
"DDInter1400",
"DDInter224"
] | Pazopanib | Bosutinib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
1250,
24,
594
]
],
[
[
1250,
18,
2466
],
[
2466,
45,
594
]
],
[
[
1250,
6,
13851
],
[
13851,
45,
594
]
],
[
[
1250,
7,
2065
],
[
2065,... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Pazopanib",
"{u} (Compound) downregulates {v} (Gene)",
"PTK2"
],
[
"PTK2",
"{u} (Gene) is bound by {v} (Compound)"... | Pazopanib (Compound) downregulates PTK2 (Gene) and PTK2 (Gene) is bound by Bosutinib (Compound)
Pazopanib (Compound) binds MAP3K19 (Gene) and MAP3K19 (Gene) is bound by Bosutinib (Compound)
Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Bosutinib (Compound)
Pazopanib (Compound) is included by Pr... |
DB01050 | DB01359 | 848 | 729 | [
"DDInter900",
"DDInter1417"
] | Ibuprofen | Penbutolol | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
848,
24,
729
]
],
[
[
848,
63,
461
],
[
461,
1,
729
]
],
[
[
848,
24,
699
],
[
699,
40,
729
]
],
[
[
848,
21,
28698
],
[
28698,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Ibuprofen (Com... |
DB00619 | DB12015 | 1,419 | 1,033 | [
"DDInter909",
"DDInter53"
] | Imatinib | Alpelisib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1419,
24,
1033
]
],
[
[
1419,
25,
1135
],
[
1135,
23,
1033
]
],
[
[
1419,
25,
154
],
[
154,
24,
1033
]
],
[
[
1419,
63,
576
],
[
576,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Imatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Imatinib may lead to a major life threatening interaction when taken with Lurasidone and Lurasidone may cause a moderate interaction t... |
DB00289 | DB12245 | 847 | 823 | [
"DDInter132",
"DDInter1863"
] | Atomoxetine | Triclabendazole | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
847,
24,
823
]
],
[
[
847,
23,
112
],
[
112,
23,
823
]
],
[
[
847,
24,
1010
],
[
1010,
24,
823
]
],
[
[
847,
24,
1619
],
[
1619,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine a... |
DB00214 | DB08907 | 1,028 | 1,344 | [
"DDInter1836",
"DDInter280"
] | Torasemide | Canagliflozin | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1028,
24,
1344
]
],
[
[
1028,
24,
549
],
[
549,
1,
1344
]
],
[
[
1028,
21,
28873
],
[
28873,
60,
1344
]
],
[
[
1028,
24,
1033
],
[
103... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Torasemide (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Canagliflozin (Compound)
Torasemide may cause a mod... |
DB06176 | DB08901 | 1,342 | 1,468 | [
"DDInter1616",
"DDInter1492"
] | Romidepsin | Ponatinib | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1342,
24,
1468
]
],
[
[
1342,
64,
478
],
[
478,
24,
1468
]
],
[
[
1342,
63,
1559
],
[
1559,
23,
1468
]
],
[
[
1342,
24,
286
],
[
286,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
... | Romidepsin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a m... |
DB00960 | DB08816 | 887 | 578 | [
"DDInter1471",
"DDInter1802"
] | Pindolol | Ticagrelor | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Minor | 0 | [
[
[
887,
23,
578
]
],
[
[
887,
21,
28762
],
[
28762,
60,
578
]
],
[
[
887,
1,
699
],
[
699,
23,
578
]
],
[
[
887,
25,
1011
],
[
1011,
... | [
[
[
"Pindolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Pindolol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v... | Pindolol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Pindolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Pindolol may lead to a major life threatening interaction ... |
DB01254 | DB09498 | 1,213 | 810 | [
"DDInter484",
"DDInter1715"
] | Dasatinib | Strontium chloride Sr-89 | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
1213,
24,
810
]
],
[
[
1213,
63,
1555
],
[
1555,
24,
810
]
],
[
[
1213,
64,
273
],
[
273,
24,
810
]
],
[
[
1213,
24,
310
],
[
310,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Dasatinib may lead to a major life threatening interaction when taken with Tositumomab and Tositu... |
DB09052 | DB11601 | 250 | 1,270 | [
"DDInter220",
"DDInter1889"
] | Blinatumomab | Tuberculin purified protein derivative | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
250,
24,
1270
]
],
[
[
250,
63,
1531
],
[
1531,
24,
1270
]
],
[
[
250,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
250,
25,
1259
],
[
1259,
... | [
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Blinatumomab may lead to a major life threatening interaction when taken with Cl... |
DB01069 | DB08899 | 401 | 129 | [
"DDInter1533",
"DDInter649"
] | Promethazine | Enzalutamide | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
401,
24,
129
]
],
[
[
401,
24,
918
],
[
918,
1,
129
]
],
[
[
401,
6,
12523
],
[
12523,
45,
129
]
],
[
[
401,
21,
28703
],
[
28703,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound)
Promethazine (Compound) causes Pruritus (Side Effect) ... |
DB01261 | DB11255 | 170 | 1,371 | [
"DDInter1679",
"DDInter374"
] | Sitagliptin | Chromium picolinate | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Moderate | 1 | [
[
[
170,
24,
1371
]
],
[
[
170,
63,
245
],
[
245,
24,
1371
]
],
[
[
170,
24,
1296
],
[
1296,
24,
1371
]
],
[
[
170,
23,
52
],
[
52,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin ... |
DB00701 | DB12141 | 1,091 | 971 | [
"DDInter90",
"DDInter817"
] | Amprenavir | Gilteritinib | Amprenavir is a protease inhibitor used to treat HIV infection. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
1091,
25,
971
]
],
[
[
1091,
25,
1135
],
[
1135,
23,
971
]
],
[
[
1091,
23,
466
],
[
466,
62,
971
]
],
[
[
1091,
64,
1181
],
[
1181,
... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Amprenavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause ... |
DB00465 | DB00877 | 886 | 629 | [
"DDInter1010",
"DDInter1678"
] | Ketorolac | Sirolimus | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
886,
25,
629
]
],
[
[
886,
7,
3603
],
[
3603,
46,
629
]
],
[
[
886,
18,
3222
],
[
3222,
46,
629
]
],
[
[
886,
18,
20113
],
[
20113,
... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Ketorolac",
"{u} (Compound) upregulates {v} (Gene)",
"ZFP36"
],
[
"ZFP36",
"{u} (Gene) is upregulated by {v} (Compound)",
"... | Ketorolac (Compound) upregulates ZFP36 (Gene) and ZFP36 (Gene) is upregulated by Sirolimus (Compound)
Ketorolac (Compound) downregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Sirolimus (Compound)
Ketorolac (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Sirolimus (Compound)
Ketorolac ... |
DB05239 | DB08875 | 866 | 1,618 | [
"DDInter425",
"DDInter262"
] | Cobimetinib | Cabozantinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
866,
24,
1618
]
],
[
[
866,
64,
723
],
[
723,
24,
1618
]
],
[
[
866,
25,
384
],
[
384,
63,
1618
]
],
[
[
866,
24,
165
],
[
165,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepi... | Cobimetinib may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Cobimetinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate ... |
DB00981 | DB11160 | 1,528 | 337 | [
"DDInter1462",
"DDInter1459"
] | Physostigmine | Phenyltoloxamine | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the... | Moderate | 1 | [
[
[
1528,
24,
337
]
],
[
[
1528,
24,
820
],
[
820,
24,
337
]
],
[
[
1528,
63,
999
],
[
999,
24,
337
]
],
[
[
1528,
24,
820
],
[
820,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Thiethy... |
DB00835 | DB03128 | 100 | 140 | [
"DDInter245",
"DDInter18"
] | Brompheniramine | Acetylcholine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken ... | Moderate | 1 | [
[
[
100,
24,
140
]
],
[
[
100,
35,
1376
],
[
1376,
24,
140
]
],
[
[
100,
63,
999
],
[
999,
24,
140
]
],
[
[
100,
24,
104
],
[
104,
2... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylcholine"
]
],
[
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases... | Brompheniramine (Compound) resembles Diphenhydramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine
Brompheniramine may cause ... |
DB00425 | DB00619 | 558 | 1,419 | [
"DDInter1970",
"DDInter909"
] | Zolpidem | Imatinib | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
558,
24,
1419
]
],
[
[
558,
6,
6017
],
[
6017,
45,
1419
]
],
[
[
558,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
558,
24,
222
],
[
222,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Zolpidem (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Imatinib (Compound)
Zolpidem (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutra... |
DB00352 | DB01017 | 482 | 1,669 | [
"DDInter1814",
"DDInter1224"
] | Tioguanine | Minocycline | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
482,
24,
1669
]
],
[
[
482,
24,
45
],
[
45,
23,
1669
]
],
[
[
482,
24,
663
],
[
663,
24,
1669
]
],
[
[
482,
63,
912
],
[
912,
24... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine may cause a minor interaction that can limit clinical effects when taken with Minocycline
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Metho... |
DB00563 | DB00624 | 663 | 1,561 | [
"DDInter1174",
"DDInter1776"
] | Methotrexate | Testosterone (topical) | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Testosterone is an androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17beta-hydroxy steroid, an androstanoid, a C19-steroid and a 3-oxo-Delta(4) steroid. | Moderate | 1 | [
[
[
663,
24,
1561
]
],
[
[
663,
24,
155
],
[
155,
1,
1561
]
],
[
[
663,
24,
870
],
[
870,
63,
1561
]
],
[
[
663,
24,
1026
],
[
1026,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Testosterone (Compound)
Methotrexate may cause a moderate intera... |
DB00358 | DB05316 | 1,010 | 749 | [
"DDInter1140",
"DDInter1467"
] | Mefloquine | Pimavanserin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
1010,
24,
749
]
],
[
[
1010,
23,
112
],
[
112,
23,
749
]
],
[
[
1010,
24,
1264
],
[
1264,
24,
749
]
],
[
[
1010,
63,
521
],
[
521,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxep... |
DB00294 | DB01124 | 1,336 | 1,411 | [
"DDInter701",
"DDInter1828"
] | Etonogestrel | Tolbutamide | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1336,
24,
1411
]
],
[
[
1336,
24,
959
],
[
959,
40,
1411
]
],
[
[
1336,
63,
245
],
[
245,
40,
1411
]
],
[
[
1336,
21,
28746
],
[
28746... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Comp... |
DB01175 | DB04837 | 318 | 649 | [
"DDInter672",
"DDInter407"
] | Escitalopram | Clofedanol | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
318,
24,
649
]
],
[
[
318,
63,
1376
],
[
1376,
24,
649
]
],
[
[
318,
63,
832
],
[
832,
40,
649
]
],
[
[
318,
64,
401
],
[
401,
2... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],... | Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Tripele... |
DB00994 | DB01330 | 361 | 1,402 | [
"DDInter1277",
"DDInter324"
] | Neomycin | Cefotetan | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. | Moderate | 1 | [
[
[
361,
24,
1402
]
],
[
[
361,
24,
1124
],
[
1124,
1,
1402
]
],
[
[
361,
24,
1558
],
[
1558,
40,
1402
]
],
[
[
361,
63,
277
],
[
277,
... | [
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotetan"
]
],
[
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
],
[
... | Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole and Cefamandole (Compound) resembles Cefotetan (Compound)
Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin and Cefoxitin (Compound) resembles Cefotetan (Compound)
Neomyc... |
DB00836 | DB09488 | 543 | 103 | [
"DDInter1088",
"DDInter23"
] | Loperamide | Acrivastine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
543,
24,
103
]
],
[
[
543,
24,
1405
],
[
1405,
24,
103
]
],
[
[
543,
63,
85
],
[
85,
24,
103
]
],
[
[
543,
25,
1671
],
[
1671,
2... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Atropine a... |
DB00641 | DB00704 | 467 | 267 | [
"DDInter1675",
"DDInter1263"
] | Simvastatin | Naltrexone | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
467,
24,
267
]
],
[
[
467,
6,
4973
],
[
4973,
45,
267
]
],
[
[
467,
7,
3163
],
[
3163,
46,
267
]
],
[
[
467,
18,
2900
],
[
2900,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Simvastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Simvastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Naltrexone (Compound)
Simvastatin (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Naltrexone (Compound)
Simvastatin (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Naltrexone (Compound)
Simvastat... |
DB01098 | DB06723 | 14 | 115 | [
"DDInter1622",
"DDInter58"
] | Rosuvastatin | Aluminum hydroxide | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
14,
24,
115
]
],
[
[
14,
21,
28643
],
[
28643,
60,
115
]
],
[
[
14,
63,
1072
],
[
1072,
23,
115
]
],
[
[
14,
24,
1191
],
[
1191,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Eff... | Rosuvastatin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with... |
DB00046 | DB01241 | 1,179 | 1,206 | [
"DDInter940",
"DDInter812"
] | Insulin lispro | Gemfibrozil | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA appr... | Moderate | 1 | [
[
[
1179,
24,
1206
]
],
[
[
1179,
24,
1476
],
[
1476,
62,
1206
]
],
[
[
1179,
24,
590
],
[
590,
24,
1206
]
],
[
[
1179,
24,
1040
],
[
1040... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Gemfibrozil
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide ... |
DB01211 | DB01222 | 609 | 617 | [
"DDInter393",
"DDInter246"
] | Clarithromycin | Budesonide | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Major | 2 | [
[
[
609,
25,
617
]
],
[
[
609,
63,
1351
],
[
1351,
1,
617
]
],
[
[
609,
64,
175
],
[
175,
1,
617
]
],
[
[
609,
24,
1220
],
[
1220,
1... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flunisolide"
],
[
"F... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Clarithromycin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Budesonide (Compound)... |
DB00468 | DB12267 | 1,424 | 1,476 | [
"DDInter1557",
"DDInter233"
] | Quinine | Brigatinib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1424,
24,
1476
]
],
[
[
1424,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
1424,
23,
1135
],
[
1135,
23,
1476
]
],
[
[
1424,
25,
230
],
[
230... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Quinine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may c... |
DB00468 | DB00734 | 1,424 | 1,664 | [
"DDInter1557",
"DDInter1605"
] | Quinine | Risperidone | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
1424,
24,
1664
]
],
[
[
1424,
25,
924
],
[
924,
40,
1664
]
],
[
[
1424,
24,
519
],
[
519,
40,
1664
]
],
[
[
1424,
6,
4973
],
[
4973,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
... | Quinine may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Risperidone (Compound)
Quinine (Comp... |
DB01177 | DB05812 | 77 | 1,374 | [
"DDInter904",
"DDInter8"
] | Idarubicin | Abiraterone | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
77,
24,
1374
]
],
[
[
77,
6,
10417
],
[
10417,
45,
1374
]
],
[
[
77,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
77,
24,
74
],
[
74,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Idarubicin",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
... | Idarubicin (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Abiraterone (Compound)
Idarubicin (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Idarubicin may cause a moderate interaction that could exacerbate diseases when ta... |
DB00460 | DB04951 | 612 | 187 | [
"DDInter1929",
"DDInter1477"
] | Verteporfin | Pirfenidone | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
612,
24,
187
]
],
[
[
612,
24,
92
],
[
92,
24,
187
]
],
[
[
612,
63,
1018
],
[
1018,
24,
187
]
],
[
[
612,
25,
213
],
[
213,
25,... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
],
... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and ... |
DB00363 | DB11718 | 695 | 927 | [
"DDInter419",
"DDInter640"
] | Clozapine | Encorafenib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
695,
25,
927
]
],
[
[
695,
23,
112
],
[
112,
23,
927
]
],
[
[
695,
24,
720
],
[
720,
24,
927
]
],
[
[
695,
25,
372
],
[
372,
24,... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Clozapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mine... |
DB01278 | DB01591 | 1,021 | 667 | [
"DDInter1506",
"DDInter1696"
] | Pramlintide | Solifenacin | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1021,
24,
667
]
],
[
[
1021,
63,
104
],
[
104,
24,
667
]
],
[
[
1021,
24,
98
],
[
98,
63,
667
]
],
[
[
1021,
24,
1154
],
[
1154,
... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and S... |
DB08882 | DB15093 | 1,281 | 1,654 | [
"DDInter1070",
"DDInter1698"
] | Linagliptin | Somapacitan | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1281,
24,
1654
]
],
[
[
1281,
63,
168
],
[
168,
23,
1654
]
],
[
[
1281,
63,
176
],
[
176,
24,
1654
]
],
[
[
1281,
24,
1019
],
[
1019,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and... |
DB00006 | DB10344 | 942 | 992 | [
"DDInter217",
"DDInter818"
] | Bivalirudin | Ginger | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
942,
24,
992
]
],
[
[
942,
64,
1578
],
[
1578,
24,
992
]
],
[
[
942,
25,
1421
],
[
1421,
63,
992
]
],
[
[
942,
25,
1167
],
[
1167,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
... | Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Bivalirudin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interact... |
DB00196 | DB00402 | 600 | 1,407 | [
"DDInter743",
"DDInter685"
] | Fluconazole | Eszopiclone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Moderate | 1 | [
[
[
600,
24,
1407
]
],
[
[
600,
6,
6017
],
[
6017,
45,
1407
]
],
[
[
600,
21,
28936
],
[
28936,
60,
1407
]
],
[
[
600,
24,
1619
],
[
1619,... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eszopiclone"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound... | Fluconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Eszopiclone (Compound)
Fluconazole (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Eszopiclone (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Rucapa... |
DB09118 | DB09330 | 1,580 | 985 | [
"DDInter1711",
"DDInter1352"
] | Stiripentol | Osimertinib | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1580,
24,
985
]
],
[
[
1580,
63,
168
],
[
168,
23,
985
]
],
[
[
1580,
63,
1478
],
[
1478,
24,
985
]
],
[
[
1580,
24,
283
],
[
283,
... | [
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaf... |
DB00569 | DB00712 | 553 | 1,274 | [
"DDInter775",
"DDInter763"
] | Fondaparinux | Flurbiprofen | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Major | 2 | [
[
[
553,
25,
1274
]
],
[
[
553,
25,
935
],
[
935,
63,
1274
]
],
[
[
553,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
553,
23,
297
],
[
297,
... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
... | Fondaparinux may lead to a major life threatening interaction when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Fondaparinux (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen ... |
DB00780 | DB01124 | 551 | 1,411 | [
"DDInter1440",
"DDInter1828"
] | Phenelzine | Tolbutamide | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
551,
24,
1411
]
],
[
[
551,
24,
959
],
[
959,
40,
1411
]
],
[
[
551,
63,
245
],
[
245,
40,
1411
]
],
[
[
551,
6,
10215
],
[
10215,
... | [
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB00041 | DB01042 | 1,648 | 1,307 | [
"DDInter38",
"DDInter1144"
] | Aldesleukin | Melphalan | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
1648,
24,
1307
]
],
[
[
1648,
23,
956
],
[
956,
62,
1307
]
],
[
[
1648,
23,
739
],
[
739,
23,
1307
]
],
[
[
1648,
24,
322
],
[
322,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
],
[
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Melphalan
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomeflo... |
DB11642 | DB12500 | 938 | 283 | [
"DDInter1480",
"DDInter714"
] | Pitolisant | Fedratinib | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
938,
24,
283
]
],
[
[
938,
25,
351
],
[
351,
23,
283
]
],
[
[
938,
64,
1593
],
[
1593,
23,
283
]
],
[
[
938,
63,
1419
],
[
1419,
... | [
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Pitolisant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib... | Pitolisant may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Pitolisant may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor interacti... |
DB00900 | DB06186 | 45 | 1,439 | [
"DDInter544",
"DDInter969"
] | Didanosine | Ipilimumab | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
45,
24,
1439
]
],
[
[
45,
63,
912
],
[
912,
24,
1439
]
],
[
[
45,
24,
310
],
[
310,
63,
1439
]
],
[
[
45,
24,
458
],
[
458,
24,
... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
... | Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Cabaz... |
DB00213 | DB01269 | 837 | 38 | [
"DDInter1388",
"DDInter1386"
] | Pantoprazole | Panitumumab | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006. | Moderate | 1 | [
[
[
837,
24,
38
]
],
[
[
837,
1,
1215
],
[
1215,
24,
38
]
],
[
[
837,
1,
1215
],
[
1215,
40,
660
],
[
660,
24,
38
]
],
[
[
837,
1,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panitumumab"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause ... | Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Panitumumab
Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a mode... |
DB01069 | DB05381 | 401 | 172 | [
"DDInter1533",
"DDInter863"
] | Promethazine | Histamine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Moderate | 1 | [
[
[
401,
24,
172
]
],
[
[
401,
24,
1264
],
[
1264,
24,
172
]
],
[
[
401,
63,
1242
],
[
1242,
24,
172
]
],
[
[
401,
24,
337
],
[
337,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histamine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizin... |
DB00574 | DB09268 | 121 | 1,662 | [
"DDInter717",
"DDInter1464"
] | Fenfluramine | Picosulfuric acid | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
121,
24,
1662
]
],
[
[
121,
24,
1164
],
[
1164,
24,
1662
]
],
[
[
121,
63,
1027
],
[
1027,
24,
1662
]
],
[
[
121,
25,
93
],
[
93,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Piroxi... |
DB00520 | DB08912 | 1,358 | 1,040 | [
"DDInter306",
"DDInter462"
] | Caspofungin | Dabrafenib | Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of th... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1358,
24,
1040
]
],
[
[
1358,
6,
13478
],
[
13478,
45,
1040
]
],
[
[
1358,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
1358,
63,
1101
],
[
... | [
[
[
"Caspofungin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Caspofungin",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B3"
],
[
"SLCO1B3",
"{u} (Gene) is bound by {v} (Compoun... | Caspofungin (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Dabrafenib (Compound)
Caspofungin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Caspofungin may cause a moderate interaction that could exacerbate diseases when taken with Bexa... |
DB00341 | DB00683 | 1,242 | 1,382 | [
"DDInter343",
"DDInter1212"
] | Cetirizine | Midazolam | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
1242,
24,
1382
]
],
[
[
1242,
24,
1216
],
[
1216,
40,
1382
]
],
[
[
1242,
63,
905
],
[
905,
40,
1382
]
],
[
[
1242,
21,
28883
],
[
288... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Midazolam (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Midazolam (Compound)
Ceti... |
DB01110 | DB11703 | 86 | 405 | [
"DDInter1209",
"DDInter9"
] | Miconazole | Acalabrutinib | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
86,
24,
405
]
],
[
[
86,
62,
690
],
[
690,
24,
405
]
],
[
[
86,
24,
951
],
[
951,
24,
405
]
],
[
[
86,
24,
484
],
[
484,
63,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rifabutin"
],
[
... | Miconazole may cause a minor interaction that can limit clinical effects when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palboc... |
DB00074 | DB00163 | 1,309 | 1,461 | [
"DDInter166",
"DDInter1943"
] | Basiliximab | Vitamin E | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermenta... | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Minor | 0 | [
[
[
1309,
23,
1461
]
],
[
[
1309,
64,
581
],
[
581,
23,
1461
]
],
[
[
1309,
25,
1510
],
[
1510,
62,
1461
]
],
[
[
1309,
24,
66
],
[
66,
... | [
[
[
"Basiliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Basiliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab"... | Basiliximab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Basiliximab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a minor in... |
DB08826 | DB09054 | 1,292 | 384 | [
"DDInter489",
"DDInter905"
] | Deferiprone | Idelalisib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
1292,
25,
384
]
],
[
[
1292,
63,
72
],
[
72,
24,
384
]
],
[
[
1292,
25,
725
],
[
725,
63,
384
]
],
[
[
1292,
64,
328
],
[
328,
2... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
"Eltromb... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Deferiprone may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab ma... |
DB06704 | DB09241 | 247 | 1,629 | [
"DDInter952",
"DDInter1186"
] | Iobenguane (I-131) | Methylene blue | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
247,
25,
1629
]
],
[
[
247,
76,
1000
],
[
1000,
24,
1629
]
],
[
[
247,
64,
1290
],
[
1290,
24,
1629
]
],
[
[
247,
63,
851
],
[
851,
... | [
[
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening in... | Iobenguane may lead to a major life threatening interaction when taken with Methylene blue
Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Iobenguane may lead to a major life threatening interaction when taken with Guanadrel and Guanadrel may cause a moderate int... |
DB00341 | DB01156 | 1,242 | 593 | [
"DDInter343",
"DDInter252"
] | Cetirizine | Bupropion | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
1242,
24,
593
]
],
[
[
1242,
21,
29491
],
[
29491,
60,
593
]
],
[
[
1242,
24,
536
],
[
536,
24,
593
]
],
[
[
1242,
24,
957
],
[
957,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Dental caries"
],
[
"Dental caries",
"{u} (Side Effect) ... | Cetirizine (Compound) causes Dental caries (Side Effect) and Dental caries (Side Effect) is caused by Bupropion (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00969 | DB09330 | 2 | 985 | [
"DDInter52",
"DDInter1352"
] | Alosetron | Osimertinib | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
2,
24,
985
]
],
[
[
2,
63,
1684
],
[
1684,
24,
985
]
],
[
[
2,
24,
1033
],
[
1033,
63,
985
]
],
[
[
2,
64,
529
],
[
529,
24,
... | [
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caffeine"
],
[
... | Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib ma... |
DB09054 | DB12035 | 384 | 943 | [
"DDInter905",
"DDInter1641"
] | Idelalisib | Sarecycline | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
384,
24,
943
]
],
[
[
384,
64,
1135
],
[
1135,
23,
943
]
],
[
[
384,
63,
1181
],
[
1181,
24,
943
]
],
[
[
384,
25,
1456
],
[
1456,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol"... | Idelalisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a... |
DB06212 | DB11979 | 165 | 1,320 | [
"DDInter1833",
"DDInter625"
] | Tolvaptan | Elagolix | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
165,
24,
1320
]
],
[
[
165,
63,
79
],
[
79,
24,
1320
]
],
[
[
165,
25,
129
],
[
129,
24,
1320
]
],
[
[
165,
24,
26
],
[
26,
24,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"... | Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Tolvaptan may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a ... |
DB00261 | DB15066 | 702 | 445 | [
"DDInter93",
"DDInter821"
] | Anagrelide | Givosiran | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
702,
24,
445
]
],
[
[
702,
24,
1039
],
[
1039,
24,
445
]
],
[
[
702,
25,
1555
],
[
1555,
24,
445
]
],
[
[
702,
63,
1684
],
[
1684,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Anagrelide may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin... |
DB00031 | DB06754 | 20 | 707 | [
"DDInter1764",
"DDInter471"
] | Tenecteplase | Danaparoid | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
20,
25,
707
]
],
[
[
20,
23,
944
],
[
944,
62,
707
]
],
[
[
20,
24,
298
],
[
298,
63,
707
]
],
[
[
20,
24,
901
],
[
901,
24,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile... | Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C... |
DB00916 | DB01015 | 112 | 1,247 | [
"DDInter1202",
"DDInter1724"
] | Metronidazole | Sulfamethoxazole | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
112,
23,
1247
]
],
[
[
112,
63,
10
],
[
10,
1,
1247
]
],
[
[
112,
6,
3486
],
[
3486,
45,
1247
]
],
[
[
112,
21,
29455
],
[
29455,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
... | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) resembles Sulfamethoxazole (Compound)
Metronidazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfamethoxazole (Compound)
Metronidazole (Compound) causes Agranulocytosis (Side ... |
DB00980 | DB01181 | 969 | 1,532 | [
"DDInter1564",
"DDInter906"
] | Ramelteon | Ifosfamide | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
969,
24,
1532
]
],
[
[
969,
6,
8374
],
[
8374,
45,
1532
]
],
[
[
969,
21,
28996
],
[
28996,
60,
1532
]
],
[
[
969,
63,
1648
],
[
1648,... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Ramelteon",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Ramelteon (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ifosfamide (Compound)
Ramelteon (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Ifosfamide (Compound)
Ramelteon may cause a moderate interaction that could exacerbate diseases when... |
DB00023 | DB00649 | 305 | 231 | [
"DDInter127",
"DDInter1710"
] | Asparaginase Escherichia coli | Stavudine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Moderate | 1 | [
[
[
305,
24,
231
]
],
[
[
305,
24,
139
],
[
139,
1,
231
]
],
[
[
305,
25,
375
],
[
375,
63,
231
]
],
[
[
305,
64,
1057
],
[
1057,
24... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Stavudine (Compound)
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may c... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.